Yue Sai Biology completes nearly 100 million yuan A+ round of strategic financing.

Recently, Shanghai Guotou Leading Biomedical Industry Mother Fund and Pudong Venture Capital Group's Leading District Fund jointly completed the A+ round strategic financing for Shanghai Yuexing Biological Technology Co., Ltd. The financing funds will be used to accelerate the company's research pipeline and clinical trial progress, further deepen the scale development and industrialization of innovative cell therapy drugs.